Dataset from A Randomized, Double-Blind, Double-Dummy, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of Oral Once-Daily Administration of TAK-438 10 or 20 mg Compared to Lansoprazole 15 mg in the Maintenance Treatment of Subjects With Endoscopic Healing of Erosive Esophagitis

This is a comparative study of vonoprazan (TAK-438) (10 mg or 20 mg) in participants in whom
endoscopic healing of erosive esophagitis has been confirmed with vonoprazan or adequate
treatment with a proton pump inhibitor (PPI), to demonstrate the non-inferiority of
vonoprazan to lansoprazole in their maintenance treatment (6 months or 24 weeks) as well as
to determine the clinically recommended dose for vonoprazan for maintenance therapy in
erosive esophagitis.